Citi analyst Samantha Semenkow initiated coverage of Allogene Therapeutics with a Buy rating and $7 price target. Allogene is a clinical staged biotech focused on developing allogeneic CAR-Ts for the treatment of cancer, the analyst tells investors in a research note. The firm says the company’s lead asset, ALLO-501A, is currently in registrational studies and has the potential to be the first FDA approved allogeneic CAR-T. Allogene has demonstrated that ALLO-501A combined with an optimized manufacturing process and lymphodepletion regimen can induce durable response rates in line with autologous benchmarks.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on ALLO:
- Allogene Therapeutics price target lowered to $12 from $23 at H.C. Wainwright
- Allogene Therapeutics (NASDAQ:ALLO) Blasts Up on Earnings, New Data
- Allogene Therapeutics presents preclinical data on allogeneic CAR T candidate
- Allogene Therapeutics Presents Preclinical Data on a Novel Allogeneic CAR T Product Candidate Targeting Claudin18.2 at the Society for Immunotherapy of Cancer Annual Meeting
- Allogene Therapeutics Presents Preclinical Data on Next Generation Cloak™ and Dagger™ Technologies at the Society for Immunotherapy of Cancer Annual Meeting